FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Allan Lipton

Research Profile

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Treatment Outcome

Co-author Network

Publications

TOP 3
Allan Lipton; Pablo Maroto; Michael Rader; Gary E Richardson; Fred Saad; Salvatore Siena; Alison T Stopeck; Maria Viniegra; Denise A Yardley; Philippe Beuzeboc; Boris Bilynskyy; Ada Braun; Janet E Brown; Veena Charu; Michael Clemens; Karim Fizazi; David H Henry; Chunlei Ke; Susie Jun
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.
Allan Lipton; Arun Balakumaran
Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors.
Allan Lipton; Matthew R Smith; Georgiana K Ellis; Carsten Goessl
Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Allan Lipton (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Allan Lipton; Pablo Maroto; Michael Rader; Gary E Richardson; Fred Saad; Salvatore Siena; Alison T Stopeck; Maria Viniegra; Denise A Yardley; Philippe Beuzeboc; Boris Bilynskyy; Ada Braun; Janet E Brown; Veena Charu; Michael Clemens; Karim Fizazi; David H Henry; Chunlei Ke; Susie Jun
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.
European journal of cancer (Oxford, England : 1990) 2012;48(16):3082-92.
2012: Allan Lipton; Arun Balakumaran
Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors.
Expert review of clinical pharmacology 2012;5(4):359-71.
2012: Allan Lipton; Matthew R Smith; Georgiana K Ellis; Carsten Goessl
Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab.
Clinical Medicine Insights. Oncology 2012;6():287-303.
2011: Allan Lipton; Suhail M Ali; Walter Carney; Robert Gagnon; Kim Leitzel; Anne-Marie Martin; Greg Platek; Klaudia Steplewski; Ron Westlund; Julie Maltzman
Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy.
Cancer 2011;117(21):5013-20.
2011: Allan Lipton; Kathleen I Pritchard; Lois E Shepherd; Carolyn F Wilson; Suhail M Ali; Judy-Anne W Chapman; Laurence Demers; Lei Han; Kim Leitzel; Michael Pollak
Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: results of NCIC CTG MA.14.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(27):3605-10.
2011: Shanthi Sivendran; Harold Harvey; Allan Lipton; Joseph Drabick
Treatment of Langerhans cell histiocytosis bone lesions with zoledronic acid: a case series.
International journal of hematology 2011;93(6):782-6.
2011: Allan Lipton
Improving progression-free and overall survival in patients with cancer: a potential role for bisphosphonates.
Expert opinion on pharmacotherapy 2011;12(5):749-62.
2011: Allan Lipton
Denosumab in breast cancer.
Current oncology reports 2011;13(1):1-4.
2011: Allan Lipton; Luis Costa; Robert E Coleman
Bone turnover markers: tools for prognosis and monitoring response to bisphosphonates?
Breast disease 2011;33(2):59-69.
2010: Allan Lipton; Wolfgang J Köstler; Kim Leitzel; Suhail M Ali; Jeff Sperinde; Jodi Weidler; Agnes Paquet; Thomas Sherwood; Weidong Huang; Michael Bates
Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
Cancer 2010;116(22):5168-78.
2010: Jonathan Green; Allan Lipton
Anticancer properties of zoledronic acid.
Cancer investigation 2010;28(9):944-57.
2010: Allan Lipton
Implications of bone metastases and the benefits of bone-targeted therapy.
Seminars in oncology 2010;37 Suppl 2():S15-29.
2010: Allan Lipton
Bone loss prevention in cancer: new developments and perspectives.
Seminars in oncology 2010;37 Suppl 1():S1-2.
2010: Evangelos Terpos; J Berenson; R J Cook; Allan Lipton; R E Coleman
Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease.
Leukemia 2010;24(5):1043-9.
2010: Evangelos Terpos; Meletios A Dimopoulos; Vikas Shrivastava; Kim Leitzel; Dimitrios Christoulas; Magdalini Migkou; Maria Gavriatopoulou; Konstantinos Anargyrou; Peter Hamer; Efstathios Kastritis; Walter Carney; Allan Lipton
High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents.
Leukemia research 2010;34(3):399-402.
2010: Jean-Jacques Body; Allan Lipton; Julie Gralow; Guenther G Steger; Guozhi Gao; Howard Yeh; Karim Fizazi
Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2010;25(3):440-6.
2010: Allan Lipton; Cynthia Campbell-Baird; Harold Harvey; Christian Kim; Laurence Demers; Luis Costa
Phase I trial of zoledronic acid + imatinib mesylate (Gleevec) in patients with bone metastases.
American journal of clinical oncology 2010;33(1):75-8.
2010: M N Vo; M Evans; Kim Leitzel; Suhail M Ali; M Wilson; Laurence Demers; Dean B Evans; Allan Lipton
Elevated plasma endoglin (CD105) predicts decreased response and survival in a metastatic breast cancer trial of hormone therapy.
Breast cancer research and treatment 2010;119(3):767-71.
2009: Suhail M Ali; Kim Leitzel; Allan Lipton; Walter P Carney; Wolfgang J Köstler
Value of serum human epidermal growth factor receptor 2 (HER2)/neu testing for early prediction of response to HER2/neu-directed therapies is still an open one and deserves further study in large prospective trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(36):e273; author reply e274-5.
2009: Daniel D Karp; Michael N Pollak; Roger B Cohen; Peter D Eisenberg; Paul Haluska; Donghua Yin; Allan Lipton; Laurence Demers; Kim Leitzel; Mary L Hixon; Leon W Terstappen; Linda L Garland; Luis G Paz-Ares; Felipe Cardenal; Corey J Langer; Antonio Gualberto
Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009;4(11):1397-403.
2009: Allan Lipton; Robert Uzzo; Robert J Amato; Georgiana K Ellis; Behrooz Hakimian; G David Roodman; Matthew R Smith
The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors.
Journal of the National Comprehensive Cancer Network : JNCCN 2009;7 Suppl 7():S1-29; quiz S30.
2008: Allan Lipton; Guenther G Steger; Jazmin Figueroa; Cristina Alvarado; Philippe Solal-Celigny; Jean-Jacques Body; Richard de Boer; Rossana Berardi; Pere Gascon; Katia S Tonkin; Robert E Coleman; Alexander H G Paterson; Guozhi M Gao; Amy C Kinsey; Mark C Peterson; Susie Jun
Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(20):6690-6.
2008: Suhail M Ali; Walter P Carney; Francisco J Esteva; Monica Fornier; Lyndsay Harris; Wolfgang J Köstler; Jean-Pierre Lotz; Diana Luftner; Marie-France Pichon; Allan Lipton
Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer.
Cancer 2008;113(6):1294-301.
2008: Lois Witters; Peggy Scherle; Steven Friedman; Jordan Fridman; Eian Caulder; Robert Newton; Allan Lipton
Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor.
Cancer research 2008;68(17):7083-9.
2008: Allan Lipton; Richard Cook; Fred Saad; Pierre Major; Patrick Garnero; Evangelos Terpos; Janet E Brown; Robert E Coleman
Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid.
Cancer 2008;113(1):193-201.
2008: Allan Lipton; Kim Leitzel; Hilary A Chaudri-Ross; Dean B Evans; Suhail M Ali; Laurence Demers; Peter Hamer; Sheryl Brown-Shimer; Karen Pierce; Victor Gaur; Walter Carney
Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(16):2653-8.
2007: Allan Lipton; Guenther G Steger; Jazmin Figueroa; Cristina Alvarado; Philippe Solal-Celigny; Jean-Jacques Body; Richard de Boer; Rossana Berardi; Pere Gascon; Katia S Tonkin; Robert Coleman; Alexander H G Paterson; Mark C Peterson; Michelle Fan; Amy Kinsey; Susie Jun
Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(28):4431-7.
2007: Allan Lipton; Michael Gnant; Matti Aapro
Managing aromatase inhibitor-associated bone loss in breast cancer.
Women's health (London, England) 2007;3(4):441-8.
2007: Allan Lipton; Suhail M Ali; Kim Leitzel; Laurence Demers; Dean B Evans; Peter Hamer; Sheryl Brown-Shimer; Karen Pierce; Walter P Carney
Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer.
Cancer 2007;109(10):1933-9.
2007: Allan Lipton
Treatment of bone metastases and bone pain with bisphosphonates.
Supportive cancer therapy 2007;4(2):92-100.
2007: Walter P Carney; Kim Leitzel; Suhail Ali; Rainer Neumann; Allan Lipton
HER-2/neu diagnostics in breast cancer.
Breast cancer research : BCR 2007;9(3):207.
2006: Christopher Souder; Kim Leitzel; Suhail M Ali; Laurence Demers; Dean B Evans; Hilary A Chaudri-Ross; Wolfgang Hackl; Peter Hamer; Walter P Carney; Allan Lipton
Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer.
Cancer 2006;107(10):2337-45.
2006: Allan Lipton
Future treatment of bone metastases.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(20 Pt 2):6305s-6308s.
2006: Jean-Jacques Body; Thierry Facon; Robert E Coleman; Allan Lipton; Filip Geurs; Michelle Fan; Donna L Holloway; Mark C Peterson; Pirow J Bekker
A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(4):1221-8.
2005: Allan Lipton; Kim Leitzel; Suhail M Ali; Laurence Demers; Harold A Harvey; Hilary A Chaudri-Ross; Dean Evans; Raquel Lang; Wolfgang Hackl; Peter Hamer; Walter P Carney
Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy.
Cancer 2005;104(2):257-63.
2005: Allan Lipton
New therapeutic agents for the treatment of bone diseases.
Expert opinion on biological therapy 2005;5(6):817-32.
2004: Walter P Carney; Rainer Neumann; Allan Lipton; Kim Leitzel; Suhail Ali; Chris Price
Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer.
Clinical breast cancer 2004;5(2):105-16.
2004: Allan Lipton; Kim Leitzel; Suhail Ali
Predicting response to herceptin therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(5):1559-60.
2003: Walter P Carney; Rainer Neumann; Allan Lipton; Kim Leitzel; Suhail Ali; Chris Price
Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer.
Clinical chemistry 2003;49(10):1579-98.
2003: Allan Lipton; Ming Zheng; John Seaman
Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma.
Cancer 2003;98(5):962-9.
2003: Allan Lipton; Suhail M Ali; Kim Leitzel; Laurence Demers; Harold A Harvey; Hilary A Chaudri-Ross; C Brady; P Wyld; Walter P Carney
Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(10):1967-72.
2003: Allan Lipton
Bone metastases in breast cancer.
Current treatment options in oncology 2003;4(2):151-8.
2003: Lois Witters; Samuel M Santala; Linda Engle; Vernon M Chinchilli; Allan Lipton
Decreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cells.
American journal of clinical oncology 2003;26(1):50-4.
2003: Jean-Jacques Body; Philip R Greipp; Robert E Coleman; Thierry Facon; Filip Geurs; Jean-Paul Fermand; Jean-Luc Harousseau; Allan Lipton; Xavier Mariette; Catherine D Williams; Arline Nakanishi; Donna L Holloway; Steven W Martin; Colin R Dunstan; Pirow J Bekker
A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.
Cancer 2003;97(3 Suppl):887-92.
2003: Loren E Clarke; Kim Leitzel; Jill Smith; Suhail M Ali; Allan Lipton
Epidermal growth factor receptor mRNA in peripheral blood of patients with pancreatic, lung, and colon carcinomas detected by RT-PCR.
International journal of oncology 2003;22(2):425-30.
2002: Lois Witters; Linda Engle; Allan Lipton
Restoration of estrogen responsiveness by blocking the HER-2/neu pathway.
Oncology reports 2002;9(6):1163-6.
2002: Suhail M Ali; Kim Leitzel; Vernon M Chinchilli; Linda Engle; Laurence Demers; Harold A Harvey; Walter P Carney; Jeffrey W Allard; Allan Lipton
Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer.
Clinical chemistry 2002;48(8):1314-20.
2002: Allan Lipton; Suhail M Ali; Kim Leitzel; Vernon M Chinchilli; Lois Witters; Linda Engle; Donna L Holloway; Pirow J Bekker; Colin R Dunstan
Serum osteoprotegerin levels in healthy controls and cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2306-10.
2002: Allan Lipton; Suhail M Ali; Kim Leitzel; Laurence Demers; Vernon M Chinchilli; Linda Engle; Harold A Harvey; C Brady; C M Nalin; M Dugan; Walter P Carney; J Allard
Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1467-72.
1999: J L Martin; H A Harvey; Allan Lipton; R Martin
Combined chemoradiotherapy for unresectable pancreatic cancer.
American journal of clinical oncology 1999;22(3):309-14.
1999: L A Costa; MS Kopreski; L M Demers; V M Chinchilli; R J Santen; H A Harvey; Allan Lipton
Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinoma.
Cancer 1999;85(1):100-3.
1998: Allan Lipton; Laurence Demers; E Curley; Vernon M Chinchilli; L Gaydos; Gabriel N Hortobagyi; Richard Theriault; D Clemens; L Costa; J Seaman; R Knight
Markers of bone resorption in patients treated with pamidronate.
European journal of cancer (Oxford, England : 1990) 1998;34(13):2021-6.
1998: Kim Leitzel; B Lieu; E Curley; J Smith; Vernon M Chinchilli; W Rychlik; Allan Lipton
Detection of cancer cells in peripheral blood of breast cancer patients using reverse transcription-polymerase chain reaction for epidermal growth factor receptor.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(12):3037-43.
1997: E D Eskander; H A Harvey; E Givant; Allan Lipton
Phase I study combining tumor necrosis factor with interferon-alpha and interleukin-2.
American journal of clinical oncology 1997;20(5):511-4.
1997: MS Kopreski; Floyd A Benko; C Kwee; Kim Leitzel; E Eskander; Allan Lipton; Christopher D Gocke
Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer.
British journal of cancer 1997;76(10):1293-9.
1997: L M Witters; R Kumar; V M Chinchilli; Allan Lipton
Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody.
Breast cancer research and treatment 1997;42(1):1-5.
1996: M S Kopreski; L Witters; W A Brennan; E A Buckwalter; V M Chinchilli; L M Demers; Allan Lipton
Protein tyrosine kinase activity in breast cancer and its relation to prognostic indicators.
Anticancer research 1996;16(5B):3037-41.
1996: A A Miller; Allan Lipton; I C Henderson; R Navari; M T Mulagha; J Cooper
Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma.
Cancer 1996;78(4):789-93.
1996: G H Volas; K Leitzel; Y Teramoto; H Grossberg; Laurence Demers; Allan Lipton
Serial serum c-erbB-2 levels in patients with breast carcinoma.
Cancer 1996;78(2):267-72.
1996: R Kumar; M Mandal; Allan Lipton; H Harvey; Craig Thompson
Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(7):1215-9.
1996: H A Harvey; Allan Lipton
The role of bisphosphonates in the treatment of bone metastases--the U.S. experience.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1996;4(3):213-7.
1996: M S Kopreski; Allan Lipton; H A Harvey; R Kumar
Growth inhibition of breast cancer cell lines by combinations of anti-P185HER2 monoclonal antibody and cytokines.
Anticancer research 1996;16(1):433-6.
1995: L M Demers; L Costa; Vernon M Chinchilli; L Gaydos; E Curley; Allan Lipton
Biochemical markers of bone turnover in patients with metastatic bone disease.
Clinical chemistry 1995;41(10):1489-94.
1995: L M Witters; E M Curley; R Kumar; Vernon M Chinchilli; J P Harvey; V Crebbin; H A Harvey; Allan Lipton
Epidermal growth factor receptor ectodomain in the urine of patients with squamous cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(5):551-7.
1995: K Leitzel; Y Teramoto; K Konrad; Vernon M Chinchilli; G Volas; H Grossberg; H Harvey; Laurence Demers; Allan Lipton
Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(5):1129-35.
1995: Allan Lipton; L M Demers; H A Harvey; K B Kambic; H Grossberg; C Brady; H Adlercruetz; P F Trunet; Richard J Santen
Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer.
Cancer 1995;75(8):2132-8.
1993: Allan Lipton; Laurence Demers; Y Daniloff; E Curley; C Hamilton; H Harvey; L Witters; J Seaman; R Van der Giessen; S Seyedin
Increased urinary excretion of pyridinium cross-links in cancer patients.
Clinical chemistry 1993;39(4):614-8.
1993: L M Demers; Allan Lipton; H A Harvey; K B Kambic; H Grossberg; C Brady; Richard J Santen
The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer.
The Journal of steroid biochemistry and molecular biology 1993;44(4-6):687-91.
1993: L M Demers; Allan Lipton; H A Harvey; J Hanagan; M Mulagha; Richard J Santen
The effects of long term fadrozole hydrochloride treatment in patients with advanced stage breast cancer.
The Journal of steroid biochemistry and molecular biology 1993;44(4-6):683-5.
1993: Allan Lipton; H Harvey; E Givant; K Hopper; J Lawler; Y Matthews; M Hirsh; J Zeffren
Interleukin-2 and interferon-alpha-2a outpatient therapy for metastatic renal cell carcinoma.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;13(2):122-9.
1992: Allan Lipton; Richard J Santen; Steven J Santner; H A Harvey; S I Sanders; Y L Matthews
Prognostic value of breast cancer aromatase.
Cancer 1992;70(7):1951-5.
1991: Allan Lipton; H A Harvey; Charles M Balch; C E Antle; R Heckard; Alfred A Bartolucci
Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(7):1151-6.
1991: Richard J Santen; L M Demers; J Lynch; H Harvey; Allan Lipton; M Mulagha; J Hanagan; Judy E Garber; I C Henderson; R M Navari
Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor.
The Journal of clinical endocrinology and metabolism 1991;73(1):99-106.
1990: Andrea Manni; A E Boucher; L M Demers; H A Harvey; Allan Lipton; M A Simmonds; M Bartholomew
Somatostatin analogues in the treatment of breast and prostate cancer.
The Journal of steroid biochemistry and molecular biology 1990;37(6):1083-7.
1990: G M Kochak; S Mangat; M T Mulagha; E A Entwistle; Richard J Santen; Allan Lipton; L Demers
The pharmacodynamic inhibition of estrogen synthesis by fadrozole, an aromatase inhibitor, and its pharmacokinetic disposition.
The Journal of clinical endocrinology and metabolism 1990;71(5):1349-5.
1990: M Hirsh; Allan Lipton; H Harvey; E Givant; K Hopper; G Jones; J Zeffren; D Levitt
Phase I study of interleukin-2 and interferon alfa-2a as outpatient therapy for patients with advanced malignancy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(10):1657-63.
1990: L M Demers; J C Melby; T E Wilson; Allan Lipton; H A Harvey; Richard J Santen
The effects of CGS 16949A, an aromatase inhibitor on adrenal mineralocorticoid biosynthesis.
The Journal of clinical endocrinology and metabolism 1990;70(4):1162-6.
1990: Allan Lipton; H A Harvey; L M Demers; J R Hanagan; M T Mulagha; G M Kochak; S Fitzsimmons; S I Sanders; Richard J Santen
A phase I trial of CGS 16949A. A new aromatase inhibitor.
Cancer 1990;65(6):1279-85.
1990: Allan Lipton; H A Harvey; Richard J Santen; J A Stryker; S G Barnes; B K Walker; R H Dixon; E M Givant; M J Bartholomew; C Nadjafi
FAM chemotherapy +/- aminoglutethimide in the treatment of pancreatic carcinoma.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 1990;16(1):12-4.
1989: Andrea Manni; A E Boucher; L M Demers; H A Harvey; Allan Lipton; M A Simmonds; M Bartholomew
Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer.
Breast cancer research and treatment 1989;14(3):289-98.
1989: Allan Lipton; H A Harvey; B Walker; R Dixon; D Valdivia; S Barnes; R Gordon; D White-Hershey; M J Bartholomew; N Warzawski
Chemotherapy plus RA233 in the treatment of oat cell lung cancer.
American journal of clinical oncology 1989;12(3):259-63.
1989: Allan Lipton; H A Harvey; J Glenn; W A Weidner; M Strauss; S E Miller; J B Taylor; D White-Hershey; J L Barlow
A phase I study of hepatic arterial infusion using difluoromethylornithine.
Cancer 1989;63(3):433-7.
1989: Richard J Santen; L M Demers; H Adlercreutz; H Harvey; Steven J Santner; S Sanders; Allan Lipton
Inhibition of aromatase with CGS 16949A in postmenopausal women.
The Journal of clinical endocrinology and metabolism 1989;68(1):99-106.
1988: Richard J Santen; Steven J Santner; H A Harvey; Allan Lipton; M Simmonds; P D Feil; Ernest K Manders; T S Davis
Marked heterogeneity of aromatase activity in human malignant melanoma tissue.
European journal of cancer & clinical oncology 1988;24(12):1811-6.
1988: Allan Lipton; Richard J Santen; Steven J Santner; H A Harvey; D White-Hershey; M J Bartholomew; F E Sharkey
Correlation of aromatase activity with histological differentiation of breast cancer--a morphometric analysis.
Breast cancer research and treatment 1988;12(1):31-5.
1988: Andrea Manni; M Bartholomew; R Caplan; A Boucher; Richard J Santen; Allan Lipton; H Harvey; M Simmonds; D White-Hershey; R Gordon
Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(9):1456-66.
1987: Richard J Santen; A E Boucher; Steven J Santner; I C Henderson; H Harvey; Allan Lipton
Inhibition of aromatase as treatment of breast carcinoma in postmenopausal women.
The Journal of laboratory and clinical medicine 1987;109(3):278-89.
1987: Allan Lipton; Steven J Santner; Richard J Santen; H A Harvey; P D Feil; D White-Hershey; M J Bartholomew; C E Antle
Aromatase activity in primary and metastatic human breast cancer.
Cancer 1987;59(4):779-82.
1987: Allan Lipton; Richard J Santen; H A Harvey; Andrea Manni; M A Simmonds; D White-Hershey; M J Bartholomew; B K Walker; R H Dixon; D E Valdevia
A randomized trial of aminoglutethimide +/- estrogen before chemotherapy in advanced breast cancer.
American journal of clinical oncology 1987;10(1):65-70.
1987: Andrea Manni; Richard J Santen; A E Boucher; Allan Lipton; H Harvey; M Simmonds; R Gordon; T Rohner; J Drago; J Wettlaufer
Androgen depletion and repletion as a means of potentiating the effect of cytotoxic chemotherapy in advanced prostate cancer.
Journal of steroid biochemistry 1987;27(1-3):551-6.
1987: A A Messeih; J M Schweitzer; Allan Lipton; H A Harvey; M A Simmonds; J A Stryker; J A Ricci; S L Hoffman; R J Gottleib; R H Dixon
Addition of etoposide to cyclophosphamide, doxorubicin, and vincristine for remission induction and survival in patients with small cell lung cancer.
Cancer treatment reports 1987;71(1):61-6.
1986: Andrea Manni; Richard J Santen; A E Boucher; Allan Lipton; H Harvey; M Simmonds; D White-Hershey; R A Gordon; T J Rohner; J Drago
Androgen priming and response to chemotherapy in advanced prostatic cancer.
The Journal of urology 1986;136(6):1242-6.
1986: Andrea Manni; Richard J Santen; A E Boucher; Allan Lipton; H Harvey; M Simmonds; D White-Hershey; R A Gordon; T Rohner; J Drago
Hormone stimulation and chemotherapy in advanced prostate cancer: interim analysis of an ongoing randomized trial.
Anticancer research 1986;6(2):309-14.
1985: A A Messeih; Allan Lipton; R J Santen; H A Harvey; A E Boucher; R Murray; J Ragaz; A U Buzdar; G A Nagel; I C Henderson
Aminoglutethimide-induced hematologic toxicity: worldwide experience.
Cancer treatment reports 1985;69(9):1003-4.
1985: Andrea Manni; Richard J Santen; A Boucher; Allan Lipton; H Harvey; M Simmonds; D White; R Gordon; T Ronher; J Drago
Hormone stimulation and chemotherapy in advanced prostate cancer: preliminary results of a prospective controlled clinical trial.
Anticancer research 1985;5(2):161-5.
1985: Richard J Santen; H English; T Rohner; J Drago; Allan Lipton; H Harvey; M Simmonds; A Boucher; L M Glode; J Wettlaufer
Androgen depletion/repletion in combination with chemotherapy: strategy for secondary treatment of metastatic prostatic cancer.
Progress in clinical and biological research 1985;185A():359-71.
1985: M A Simmonds; Allan Lipton; H A Harvey; N Ellison; D S White
Phase II study of mitolactol in metastatic malignant melanoma.
Cancer treatment reports 1985;69(1):65-7.
1984: Peter S Houts; Allan Lipton; H A Harvey; B Martin; M A Simmonds; R H Dixon; S Longo; T Andrews; R A Gordon; J Meloy
Nonmedical costs to patients and their families associated with outpatient chemotherapy.
Cancer 1984;53(11):2388-92.
1984: Andrea Manni; Richard J Santen; A E Boucher; Allan Lipton; H Harvey; J Drago; T Rohner; D Haagensen; M Glode; Steven J Santner
Evaluation of CEA and GCDFP-15 plasma level during hormonally induced cancer stimulation.
Anticancer research 1984;4(3):141-4.
1984: J R Drago; Richard J Santen; Allan Lipton; T J Worgul; H A Harvey; A Boucher; Andrea Manni; T J Rohner
Clinical effect of aminoglutethimide, medical adrenalectomy, in treatment of 43 patients with advanced prostatic carcinoma.
Cancer 1984;53(7):1447-50.
1983: T J Worgul; Richard J Santen; E Samojlik; J D Veldhuis; Allan Lipton; H A Harvey; J R Drago; T J Rohner
Clinical and biochemical effect of aminoglutethimide in the treatment of advanced prostatic carcinoma.
The Journal of urology 1983;129(1):51-5.
1983: Allan Lipton; H A Harvey; B Lawrence; R Gottlieb; M Kukrika; R Dixon; W Graham; S Miller; R Heckard; D Schelzel; D S White
Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma.
Cancer 1983;51(1):57-60.
1983: Peter S Houts; Allan Lipton; H A Harvey; B A Martin
A method for collecting detailed data on direct and indirect medical expenses of cancer patients.
Progress in clinical and biological research 1983;120():193-9.
1982: Richard J Santen; T J Worgul; E Samojlik; A E Boucher; Allan Lipton; H Harvey
Adequacy of estrogen suppression with aminoglutethimide and hydrocortisone as treatment of human breast cancer: correlation of hormonal data with clinical responses.
Cancer research 1982;42(8 Suppl):3397s-3401s.
1982: S A Wells; T J Worgul; E Samojlik; A E Boucher; Allan Lipton; H Harvey; D White; E Smart; C Cox; Richard J Santen
Comparison of surgical adrenalectomy to medical adrenalectomy in patients with metastatic carcinoma of the breast.
Cancer research 1982;42(8 Suppl):3454s-3457s.
1982: H A Harvey; Allan Lipton; D S White; Richard J Santen; A E Boucher; A S Shafik; R J Dixon
Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast cancer.
Cancer research 1982;42(8 Suppl):3451s-3453s.
1982: W R Wynert; H A Harvey; Allan Lipton; J Schweitzer; D S White
Phase I study of a 5-day schedule of mitoxantrone (dihydroxyanthracenedione).
Cancer treatment reports 1982;66(6):1303-6.
1982: Richard J Santen; T J Worgul; Allan Lipton; H Harvey; A Boucher; E Samojlik; S A Wells
Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma.
Annals of internal medicine 1982;96(1):94-101.
1981: Richard J Santen; T J Worgul; E Samojlik; A Interrante; A E Boucher; Allan Lipton; H A Harvey; D S White; E Smart; C Cox; S A Wells
A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer.
The New England journal of medicine 1981;305(10):545-51.
1980: B V Lawrence; Allan Lipton; H A Harvey; Richard J Santen; S A Wells; C E Cox; D S White; E K Smart
Influence of estrogen receptor status on response of metastatic breast cancer to aminoglutethimide therapy.
Cancer 1980;45(4):786-91.